Sanofi
99 years and younger
All genders
The dupilumab clinical program in EoE has provided evidence that long-term suppression of IL-4 and IL-13 could lead to progressive improvement in fibrostenosis. . There is a need for longer term assessments with comprehensive functional, histological, molecular, clinical, and endoscopic assessments to characterize the risk of fibrotic progression as well …